Identification

Name
Quinethazone
Accession Number
DB01325
Type
Small Molecule
Groups
Approved
Description

Quinethazone (INN, brand name Hydromox) is a thiazide diuretic used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low potassium levels.

Structure
Thumb
Synonyms
  • Chinetazone
  • Chinethazonum
  • Hydromox
  • Quinetazona
  • Quinethazon
  • Quinethazonum
International/Other Brands
Aquamox / Hydromox / Idrokin
Categories
UNII
455E0S048W
CAS number
73-49-4
Weight
Average: 289.739
Monoisotopic: 289.028789662
Chemical Formula
C10H12ClN3O3S
InChI Key
AGMMTXLNIQSRCG-UHFFFAOYSA-N
InChI
InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
IUPAC Name
7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
SMILES
CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O

Pharmacology

Indication

Used to treat hypertension.

Structured Indications
Not Available
Pharmacodynamics

Quinethazone is a thiazide diuretic used to treat hypertension. It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of action

As a diuretic, quinethazone inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like quinethazone also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of quinethazone is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

TargetActionsOrganism
ACarbonic anhydrase 1
inhibitor
Human
ACarbonic anhydrase 2
inhibitor
Human
ASolute carrier family 12 member 1
inhibitor
Human
ASolute carrier family 12 member 2
inhibitor
Human
ASolute carrier family 12 member 3
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Quinethazone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Quinethazone.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Quinethazone.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Quinethazone.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Quinethazone.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Quinethazone.Approved, Investigational
AceclofenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quinethazone.Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Quinethazone can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Quinethazone.Experimental
AlaproclateAlaproclate may increase the hyponatremic activities of Quinethazone.Experimental
AlclofenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Quinethazone.Approved
AlcuroniumThe serum concentration of Quinethazone can be increased when it is combined with Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Quinethazone.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Quinethazone.Approved, Illicit
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Quinethazone.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinethazone.Approved
AlminoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quinethazone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Quinethazone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Quinethazone.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Quinethazone.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved, Illicit
AndrographolideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Quinethazone.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Quinethazone.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Quinethazone.Investigational
AnisodamineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Quinethazone can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Quinethazone.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Quinethazone.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Quinethazone.Investigational
AtracuriumThe serum concentration of Quinethazone can be increased when it is combined with Atracurium.Experimental
Atracurium besylateThe serum concentration of Quinethazone can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Quinethazone can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Quinethazone.Investigational
BalsalazideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Quinethazone.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Quinethazone.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Quinethazone.Illicit
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Quinethazone.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Quinethazone.Investigational
BenactyzineThe serum concentration of Quinethazone can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilQuinethazone may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Quinethazone can be increased when it is combined with Benzatropine.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Quinethazone.Experimental, Illicit, Withdrawn
BiperidenThe serum concentration of Quinethazone can be increased when it is combined with Biperiden.Approved
BornaprineThe serum concentration of Quinethazone can be increased when it is combined with Bornaprine.Experimental
BromfenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Quinethazone.Approved
BufexamacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Quinethazone.Withdrawn
BumadizoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bumadizone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Quinethazone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quinethazone.Approved, Illicit, Vet Approved
CalcidiolQuinethazone may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolQuinethazone may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumQuinethazone may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateQuinethazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateQuinethazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateQuinethazone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateQuinethazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateQuinethazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateQuinethazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateQuinethazone may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Vet Approved
Calcium lactate gluconateQuinethazone may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateQuinethazone may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateQuinethazone may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateQuinethazone may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.Approved
CandoxatrilQuinethazone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilQuinethazone may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Quinethazone is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Quinethazone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Quinethazone.Illicit, Vet Approved
CarprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CaseinQuinethazone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Quinethazone.Approved, Investigational
ChloroquineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Quinethazone can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quinethazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Quinethazone.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quinethazone.Experimental
CilazaprilQuinethazone may increase the hypotensive activities of Cilazapril.Approved
CitalopramCitalopram may increase the hyponatremic activities of Quinethazone.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Quinethazone.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Quinethazone.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Quinethazone.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Quinethazone.Approved
ClonixinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Clonixin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quinethazone.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Quinethazone.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Quinethazone.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Quinethazone.Approved
CurcuminThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Quinethazone can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclophosphamide.Approved, Investigational
CymarinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with D-Limonene.Investigational
DapoxetineDapoxetine may increase the hyponatremic activities of Quinethazone.Investigational
DarifenacinThe serum concentration of Quinethazone can be increased when it is combined with Darifenacin.Approved, Investigational
DelaprilQuinethazone may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Quinethazone.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Quinethazone can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Quinethazone.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Quinethazone.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Quinethazone.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Quinethazone.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Quinethazone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Quinethazone.Vet Approved
DexetimideThe serum concentration of Quinethazone can be increased when it is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Quinethazone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quinethazone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Quinethazone.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicyclomineThe serum concentration of Quinethazone can be increased when it is combined with Dicyclomine.Approved
DifenpiramideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Quinethazone.Approved
DiflunisalThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Quinethazone.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Quinethazone.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quinethazone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quinethazone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quinethazone.Experimental, Illicit
DihydrotachysterolQuinethazone may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quinethazone.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Quinethazone.Approved
DobutamineDobutamine may increase the hypokalemic activities of Quinethazone.Approved
DofetilideQuinethazone may increase the QTc-prolonging activities of Dofetilide.Approved
DoxercalciferolQuinethazone may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Quinethazone.Investigational
DroxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Quinethazone.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quinethazone.Approved
DuloxetineDuloxetine may increase the hyponatremic activities of Quinethazone.Approved
DuvelisibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Quinethazone can be decreased when used in combination with E-6201.Investigational
EmeproniumThe serum concentration of Quinethazone can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quinethazone.Approved
EnalaprilQuinethazone may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatQuinethazone may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Quinethazone.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Epirizole.Approved
EquileninEquilenin may increase the hypokalemic activities of Quinethazone.Experimental
EquilinEquilin may increase the hypokalemic activities of Quinethazone.Approved
ErgocalciferolQuinethazone may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Quinethazone.Approved, Investigational
EstroneEstrone may increase the hypokalemic activities of Quinethazone.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Quinethazone.Approved
EtanautineThe serum concentration of Quinethazone can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Quinethazone.Approved
EthenzamideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Quinethazone can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Quinethazone.Approved, Illicit
EtodolacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Quinethazone.Approved
EtoricoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Quinethazone.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Quinethazone can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Quinethazone.Approved, Investigational
exisulindThe therapeutic efficacy of Quinethazone can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Quinethazone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quinethazone.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Quinethazone can be increased when it is combined with Fesoterodine.Approved
FloctafenineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Quinethazone.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Quinethazone.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Quinethazone.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Quinethazone.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Quinethazone.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Quinethazone.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Quinethazone.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Quinethazone.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Quinethazone.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Quinethazone.Approved
FlurbiprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Quinethazone.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Quinethazone.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Quinethazone.Approved, Investigational
FosinoprilQuinethazone may increase the hypotensive activities of Fosinopril.Approved
GallamineThe serum concentration of Quinethazone can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Quinethazone can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Quinethazone is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quinethazone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Quinethazone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quinethazone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quinethazone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quinethazone.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Quinethazone.Approved
GlycopyrroniumThe serum concentration of Quinethazone can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Guacetisal.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Quinethazone.Investigational
HE3286HE3286 may increase the hypokalemic activities of Quinethazone.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Quinethazone.Approved, Illicit
HexamethoniumThe serum concentration of Quinethazone can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
HigenamineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Quinethazone can be increased when it is combined with Homatropine.Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quinethazone.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinethazone.Approved, Illicit
HyoscyamineThe serum concentration of Quinethazone can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Icatibant.Approved
ImidaprilQuinethazone may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Quinethazone.Approved
IndalpineIndalpine may increase the hyponatremic activities of Quinethazone.Investigational, Withdrawn
IndobufenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indoprofen.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quinethazone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Quinethazone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quinethazone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Quinethazone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Quinethazone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quinethazone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quinethazone.Approved
Ipratropium bromideThe serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Quinethazone.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Quinethazone.Approved
IsoxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Isoxicam.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Quinethazone.Investigational
IvabradineQuinethazone may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Quinethazone.Approved
KetoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketorolac.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Quinethazone is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Leflunomide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quinethazone.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Quinethazone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quinethazone.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Quinethazone.Approved
LicoriceLicorice may increase the hypokalemic activities of Quinethazone.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Quinethazone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Quinethazone.Approved
LisinoprilQuinethazone may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lisofylline.Investigational
LithiumQuinethazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Quinethazone.Illicit
LonazolacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lornoxicam.Approved
LoxoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Masoprocol.Approved
MazaticolThe serum concentration of Quinethazone can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Quinethazone.Investigational
MecamylamineThe serum concentration of Quinethazone can be increased when it is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Quinethazone.Approved
Mefenamic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Quinethazone.Vet Approved
MeloxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Quinethazone.Experimental
MesalazineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Quinethazone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Quinethazone.Approved, Illicit
MethanthelineThe serum concentration of Quinethazone can be increased when it is combined with Methantheline.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Quinethazone.Approved
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Metildigoxin.Experimental
MetixeneThe serum concentration of Quinethazone can be increased when it is combined with Metixene.Approved
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quinethazone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Quinethazone.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Quinethazone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quinethazone.Approved, Investigational
MizoribineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mizoribine.Investigational
MoexiprilQuinethazone may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mofebutazone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quinethazone.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quinethazone.Approved
NaproxenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Quinethazone.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Quinethazone.Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Quinethazone.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nepafenac.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Quinethazone.Experimental
NifenazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NitroaspirinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nitroaspirin.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Quinethazone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Quinethazone.Approved, Illicit
OleandrinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Oleandrin.Experimental
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Quinethazone.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Quinethazone.Approved
OlopatadineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine.Approved
OmapatrilatQuinethazone may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Quinethazone.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Quinethazone.Approved
OrgoteinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Quinethazone can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Quinethazone can be increased when it is combined with Otilonium.Experimental
OuabainThe risk or severity of adverse effects can be increased when Quinethazone is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Quinethazone is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Quinethazone can be increased when it is combined with Oxitropium.Investigational
OxybutyninThe serum concentration of Quinethazone can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quinethazone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quinethazone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Quinethazone can be increased when it is combined with Oxyphenonium.Approved
PancuroniumThe serum concentration of Quinethazone can be increased when it is combined with Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Quinethazone.Approved
ParecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Parecoxib.Approved
ParicalcitolQuinethazone may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Quinethazone.Approved, Investigational
ParthenolideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Parthenolide.Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved, Vet Approved
PentoliniumThe serum concentration of Quinethazone can be increased when it is combined with Pentolinium.Approved
PerindoprilQuinethazone may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quinethazone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Quinethazone.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Quinethazone.Approved, Withdrawn
PhenglutarimideThe serum concentration of Quinethazone can be increased when it is combined with Phenglutarimide.Experimental
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Quinethazone.Experimental
PhenylbutazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quinethazone.Approved, Investigational
PipecuroniumThe serum concentration of Quinethazone can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Quinethazone.Approved
PirenzepineThe serum concentration of Quinethazone can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Quinethazone.Investigational
PiroxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pirprofen.Experimental
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Quinethazone.Approved, Investigational
PranoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pranoprofen.Experimental
PrasteronePrasterone may increase the hypokalemic activities of Quinethazone.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Quinethazone.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Quinethazone.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Quinethazone.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Quinethazone.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Quinethazone.Approved
ProcyclidineThe serum concentration of Quinethazone can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Quinethazone can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Quinethazone can be increased when it is combined with Propiverine.Investigational
PropyphenazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Quinethazone can be decreased when used in combination with PTC299.Investigational
QuinaprilQuinethazone may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinethazone can be increased when it is combined with Quinidine.Approved
RamiprilQuinethazone may increase the hypotensive activities of Ramipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinethazone.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Quinethazone.Approved, Investigational
RescinnamineQuinethazone may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.Experimental, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Quinethazone.Approved
RitodrineRitodrine may increase the hypokalemic activities of Quinethazone.Approved
RofecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quinethazone.Approved, Investigational
SalbutamolSalbutamol may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Quinethazone.Approved
SalsalateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quinethazone.Approved
ScopolamineThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved, Vet Approved
SemapimodThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Quinethazone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quinethazone.Approved, Investigational
Sodium phosphateQuinethazone may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Quinethazone can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Quinethazone.Investigational
SpiraprilQuinethazone may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Quinethazone can be decreased when used in combination with SRT501.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quinethazone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Suxibuzone.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Quinethazone.Approved
TarenflurbilThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tarenflurbil.Investigational
TemocaprilQuinethazone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Quinethazone.Approved
TeriflunomideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Teriflunomide.Approved
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Quinethazone.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Quinethazone.Approved, Vet Approved
Tiaprofenic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Quinethazone.Experimental
TinoridineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Quinethazone can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Quinethazone.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quinethazone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quinethazone.Approved
Tolfenamic AcidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolmetin.Approved
TolterodineThe serum concentration of Quinethazone can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateQuinethazone may increase the hypokalemic activities of Topiramate.Approved
ToremifeneQuinethazone may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quinethazone.Approved, Investigational
TrandolaprilQuinethazone may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tranilast.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Quinethazone.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tribenoside.Experimental
TrihexyphenidylThe serum concentration of Quinethazone can be increased when it is combined with Trihexyphenidyl.Approved
TrimethaphanThe serum concentration of Quinethazone can be increased when it is combined with Trimethaphan.Approved
TriptolideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Quinethazone.Withdrawn
TropatepineThe serum concentration of Quinethazone can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Quinethazone can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Quinethazone can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Quinethazone can be increased when it is combined with Tubocurarine.Approved
ValdecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
VecuroniumThe serum concentration of Quinethazone can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Quinethazone.Approved
VilanterolVilanterol may increase the hypokalemic activities of Quinethazone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quinethazone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Quinethazone.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Quinethazone.Withdrawn
ZofenoprilQuinethazone may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food to increase bioavailability.

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB15420
KEGG Drug
D00461
KEGG Compound
C07342
PubChem Compound
6307
PubChem Substance
46507280
ChemSpider
6068
BindingDB
25898
ChEBI
8717
ChEMBL
CHEMBL1532
Therapeutic Targets Database
DAP000955
PharmGKB
PA164760863
Wikipedia
Quinethazone
ATC Codes
C03BA02 — QuinethazoneC03BB02 — Quinethazone and potassium
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)251 °CPhysProp
water solubility150 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility2.51 mg/mLALOGPS
logP1.6ALOGPS
logP1.19ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)9.56ChemAxon
pKa (Strongest Basic)-0.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area101.29 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.34 m3·mol-1ChemAxon
Polarizability27.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier-0.7026
Caco-2 permeable-0.7327
P-glycoprotein substrateNon-substrate0.5421
P-glycoprotein inhibitor INon-inhibitor0.847
P-glycoprotein inhibitor IINon-inhibitor0.9619
Renal organic cation transporterNon-inhibitor0.8991
CYP450 2C9 substrateNon-substrate0.5767
CYP450 2D6 substrateNon-substrate0.8418
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9011
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6867
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7634
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9882
hERG inhibition (predictor II)Non-inhibitor0.9334
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01ox-1920000000-83ac1cb82abae8f21317

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolines
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aryl chlorides / Vinylogous amides / Aminosulfonyl compounds / Secondary carboxylic acid amides / Lactams / Amino acids and derivatives / Azacyclic compounds
show 5 more
Substituents
Quinazoline / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Benzenoid / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Vinylogous amide / Aminosulfonyl compound
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinazolines (CHEBI:8717)

Targets

Details
1. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem. 2008 Jul 21;6(14):2499-506. doi: 10.1039/b800767e. Epub 2008 May 29. [PubMed:18600270]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. doi: 10.1016/j.bmcl.2008.03.051. Epub 2008 Mar 20. [PubMed:18374572]
  3. Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8. [PubMed:18336309]
Details
2. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem. 2008 Jul 21;6(14):2499-506. doi: 10.1039/b800767e. Epub 2008 May 29. [PubMed:18600270]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. doi: 10.1016/j.bmcl.2008.03.051. Epub 2008 Mar 20. [PubMed:18374572]
  3. Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8. [PubMed:18336309]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Duarte JD, Cooper-DeHoff RM: Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):793-802. doi: 10.1586/erc.10.27. [PubMed:20528637]
  2. Gamba G: The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009 Oct;297(4):F838-48. doi: 10.1152/ajprenal.00159.2009. Epub 2009 May 27. [PubMed:19474192]
  3. Ellison DH: The thiazide-sensitive na-cl cotransporter and human disease: reemergence of an old player. J Am Soc Nephrol. 2003 Feb;14(2):538-40. [PubMed:12538756]
  4. Ko B, Hoover RS: Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):421-7. doi: 10.1097/MNH.0b013e32832f2fcb. [PubMed:19636250]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Duarte JD, Cooper-DeHoff RM: Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):793-802. doi: 10.1586/erc.10.27. [PubMed:20528637]
  2. Gamba G: The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009 Oct;297(4):F838-48. doi: 10.1152/ajprenal.00159.2009. Epub 2009 May 27. [PubMed:19474192]
  3. Ellison DH: The thiazide-sensitive na-cl cotransporter and human disease: reemergence of an old player. J Am Soc Nephrol. 2003 Feb;14(2):538-40. [PubMed:12538756]
  4. Ko B, Hoover RS: Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):421-7. doi: 10.1097/MNH.0b013e32832f2fcb. [PubMed:19636250]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Duarte JD, Cooper-DeHoff RM: Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):793-802. doi: 10.1586/erc.10.27. [PubMed:20528637]
  2. Gamba G: The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009 Oct;297(4):F838-48. doi: 10.1152/ajprenal.00159.2009. Epub 2009 May 27. [PubMed:19474192]
  3. Ellison DH: The thiazide-sensitive na-cl cotransporter and human disease: reemergence of an old player. J Am Soc Nephrol. 2003 Feb;14(2):538-40. [PubMed:12538756]
  4. Ko B, Hoover RS: Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):421-7. doi: 10.1097/MNH.0b013e32832f2fcb. [PubMed:19636250]

Drug created on June 30, 2007 11:21 / Updated on October 02, 2017 04:57